These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21784490)

  • 1. Re: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. T. Wolters, M. J. Roobol, P. J. van Leeuwen, R. C. van den Bergh, R. F. Hoedemaeker, G. J. van Leenders, F. H. Schröder and T. H. van der Kwast. J Urol 2011;185: 121-125.
    Moore CM; Klotz L; Emberton M
    J Urol; 2011 Sep; 186(3):1158-9; author reply 1159. PubMed ID: 21784490
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
    Connolly D; Hutton R; Keane PF
    Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
    [No Abstract]   [Full Text] [Related]  

  • 3. Erratum for the Report "Global distribution of earthworm diversity" by H. R. P. Phillips, C. A. Guerra, M. L. C. Bartz, M. J. I. Briones, G. Brown, T. W. Crowther, O. Ferlian, K. B. Gongalsky, J. van den Hoogen, J. Krebs, A. Orgiazzi, D. Routh, B. Schwarz, E. M. Bach, J. Bennett, U. Brose, T. Decaëns, B. König-Ries, M. Loreau, J. Mathieu, C. Mulder, W. H. van der Putten, K. S. Ramirez, M. C. Rillig, D. Russell, M. Rutgers, M. P. Thakur, F. T. de Vries, D. H. Wall, D. A. Wardle, M. Arai, F. O. Ayuke, G. H. Baker, R. Beauséjour, J. C. Bedano, K. Birkhofer, E. Blanchart, B. Blossey, T. Bolger, R. L. Bradley, M. A. Callaham, Y. Capowiez, M. E. Caulfield, A. Choi, F. V. Crotty, A. Dávalos, D. J. Diaz Cosin, A. Dominguez, A. E. Duhour, N. van Eekeren, C. Emmerling, L. B. Falco, R. Fernández, S. J. Fonte, C. Fragoso, A. L. C. Franco, M. Fugère, A. T. Fusilero, S. Gholami, M. J. Gundale, M. Gutiérrez López, D. K. Hackenberger, L. M. Hernández, T. Hishi, A. R. Holdsworth, M. Holmstrup, K. N. Hopfensperger, E. Huerta Lwanga, V. Huhta, T. T. Hurisso, B. V. Iannone III, M. Iordache, M. Joschko, N. Kaneko, R. Kanianska, A. M. Keith, C. A. Kelly, M. L. Kernecker, J. Klaminder, A. W. Koné, Y. Kooch, S. T. Kukkonen, H. Lalthanzara, D. R. Lammel, I. M. Lebedev, Y. Li, J. B. Jesus Lidon, N. K. Lincoln, S. R. Loss, R. Marichal, R. Matula, J. H. Moos, G. Moreno, A. Morón-Ríos, B. Muys, J. Neirynck, L. Norgrove, M. Novo, V. Nuutinen, V. Nuzzo, M. Rahman P, J. Pansu, S. Paudel, G. Pérès, L. Pérez-Camacho, R. Piñeiro, J.-F. Ponge, M. I. Rashid, S. Rebollo, J. Rodeiro-Iglesias, M. Á. Rodríguez, A. M. Roth, G. X. Rousseau, A. Rozen, E. Sayad, L. van Schaik, B. C. Scharenbroch, M. Schirrmann, O. Schmidt, B. Schröder, J. Seeber, M. P. Shashkov, J. Singh, S. M. Smith, M. Steinwandter, J. A. Talavera, D. Trigo, J. Tsukamoto, A. W. de Valença, S. J. Vanek, I. Virto, A. A. Wackett, M. W. Warren, N. H. Wehr, J. K. Whalen, M. B. Wironen, V. Wolters, I. V. Zenkova, W. Zhang, E. K. Cameron, N. Eisenhauer.
    Science; 2020 Jul; 369(6503):. PubMed ID: 32732396
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos' letter to the editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
    Joniau S; Van den Bergh L
    Eur Urol; 2013 Feb; 63(2):e21-2. PubMed ID: 23149147
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Loblaw, N. E. Fleshner, L. Klotz, D. Vesprini and B. Bapat J Urol 2017;197:335-341.
    Zhao F; Jeyapala R; Olkhov-Mitsel E; Vesprini D; Fleshner NE; Bapat B
    J Urol; 2018 May; 199(5):1354-1355. PubMed ID: 29428633
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8.
    Godtman RA; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):769-770. PubMed ID: 27210462
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    Valerio M; Emberton M; Ahmed HU
    Eur Urol; 2019 Feb; 75(2):e21-e22. PubMed ID: 30224194
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. N. Lawrentschuk, A. Finelli, T. H. Van der Kwast, P. Ryan, D. M. Bolton, N. E. Fleshner, J. Trachtenberg, L. Klotz, M. Robinette and H. Woo. J Urol 2011;185: 862-868.
    Dickinson L; Ahmed HU; Emberton M
    J Urol; 2011 Sep; 186(3):1159-60; author reply 1160-1. PubMed ID: 21784489
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
    van der Poel HG; Buckle T; Valdes Olmos R
    Eur Urol; 2013 Feb; 63(2):e20. PubMed ID: 23153744
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis
    Stavrinides V; Giganti F; Punwani S; Allen C; Kirkham A; Freeman A; Ball R; Haider A; Whitaker H; Orczyk C; Emberton M; Moore CM
    J Urol; 2020 Nov; 204(5):1065-1066. PubMed ID: 32698715
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.
    Crawford ED; Eisner J; Persson BE
    J Urol; 2013 Mar; 189(3):1168-9. PubMed ID: 23022003
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry: T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman, N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601-1606.
    Oefelein MG
    J Urol; 2012 Nov; 188(5):2020; author reply 2020-1. PubMed ID: 22999544
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Fritz H. Schröder, Monique J. Roobol. The REDUCE Trial. Eur Urol 2010;58:253-255.
    Cornel EB
    Eur Urol; 2011 Jan; 59(1):e1. PubMed ID: 20951493
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
    van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Wiegel T; Willemse PM; van Poppel H; Mottet N
    Eur Urol; 2019 Feb; 75(2):e23-e24. PubMed ID: 30237024
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy: K. E. M. van Kessel, W. Beukers, I. Lurkin, A. Ziel-van der Made, K. A. van der Keur, J. L. Boormans, L. Dyrskjøt, M. Márquez, T. F. Ørntoft, F. X. Real, U. Segersten, N. Malats, P.-U. Malmström, W. Van Criekinge and E. C. Zwarthoff J Urol 2017;197:590-595.
    Wang Z; Bi SS; Wang L
    J Urol; 2017 Jun; 197(6):1573. PubMed ID: 28259761
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6. Prebiopsy MRI: Through the Looking Glass.
    Vickers A; Carlsson SV; Cooperberg M
    Eur Urol; 2020 Sep; 78(3):314-315. PubMed ID: 32631742
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer: S. Loeb, M. G. Sanda, D. L. Broyles, S. S. Shin, C. H. Bangma, J. T. Wei, A. W. Partin, G. G. Klee, K. M. Slawin, L. S. Marks, R. H. N. van Schaik, D. W. Chan, L. J. Sokoll, A. B. Cruz, I. A. Mizrahi and W. J. Catalona J Urol 2015;193:1163-1169.
    Shah N; Ioffe V
    J Urol; 2015 Dec; 194(6):1825-6. PubMed ID: 26354886
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.
    Zhou X; Han X
    Eur Urol; 2019 Jul; 76(1):e15. PubMed ID: 30948226
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013;63:450-8.
    Kim KH; Rha KH
    Eur Urol; 2013 Sep; 64(3):e55-6. PubMed ID: 23746720
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.
    Van den Broeck T; Mottet N; Lam T
    Eur Urol; 2019 Jul; 76(1):e16. PubMed ID: 30967298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.